Cargando…

Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection

INTRODUCTION: Approximately 70% of veterans with hepatitis C virus infection have at least one psychiatric illness. The advent of direct-acting antiviral (DAA) therapy provided an alternative to interferon-alpha regimens and revolutionized treatment, however, the extent of psychiatric effects attrib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sackey, Bryan, Shults, Jana G., Moore, Troy A., Rogers, Rachel, Mehvar, Mina, King, Joshua G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	College of Psychiatric & Neurologic Pharmacists 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007636/ https://www.ncbi.nlm.nih.gov/pubmed/29955556 http://dx.doi.org/10.9740/mhc.2018.05.116

Ejemplares similares

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

2938. Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era within the US Veterans Health Administration
por: Varley, Cara D, et al.
Publicado: (2023)

Alcohol Use and Long‐Term Outcomes Among U.S. Veterans Who Received Direct‐Acting Antivirals for Hepatitis C Treatment
por: Kim, Nicole J., et al.
Publicado: (2020)

Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy
por: Girardin, François, et al.
Publicado: (2021)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus
por: Mada, Pradeep Kumar, et al.
Publicado: (2020)

2219. Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study
por: Butt, Adeel Ajwad, et al.
Publicado: (2018)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada
por: Chu, Cherry, et al.
Publicado: (2023)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
por: Sundberg, Isak, et al.
Publicado: (2018)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

2222. Impact of Sustained Virologic Response Achieved Through Newer Direct Acting Antivirals in Hepatitis C Infection on Diabetes Mellitus
por: Mada, Pradeep Kumar, et al.
Publicado: (2018)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
por: Gaglio, Paul J., et al.
Publicado: (2011)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
por: Rockstroh, Jürgen K, et al.
Publicado: (2013)

Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods
por: Loggi, Elisabetta, et al.
Publicado: (2017)

Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India
por: Gupta, Varun, et al.
Publicado: (2017)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
por: Gallach, Marta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a0o0mrbjlg6ie8tpki8bac7sqd